The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens.
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience / Marchetti, C.; Musella, A.; Romito, A.; Vertechy, L.; Palaia, I.; Di Donato, V.; Boccia, S.; De Felice, F.; Monti, M.; Muzii, L.; Benedetti Panici, P.. - In: ONCOLOGY. - ISSN 0030-2414. - 93:6(2017), pp. 359-366. [10.1159/000475668]
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience
Marchetti C.;Musella A.;Romito A.;Vertechy L.;Palaia I.;Di Donato V.;Boccia S.;De Felice F.;Monti M.;Muzii L.;Benedetti Panici P.
2017
Abstract
The aim of this study was to assess the efficacy and tolerability of trabectedin given every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens.File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.